Related by context. All words. (Click for frequent words.) 72 systemic anaplastic large 70 leukemia AML 70 cell lymphoma CTCL 68 leukemia CLL 67 epithelial tumors 67 metastatic malignant 66 leukemia ALL 66 Hodgkin lymphoma NHL 66 localized renal 66 tumors GIST 66 papillary renal cell carcinoma 65 invasive ductal 65 MALT lymphoma 65 grade cervical intraepithelial 65 fallopian tube carcinoma 65 basal cell carcinoma BCC 65 Myelofibrosis 65 gastrointestinal stromal tumor GIST 65 pheochromocytoma 65 cell lymphomas 65 cell acute lymphoblastic 65 gastrointestinal stromal tumor 65 refractory chronic lymphocytic 65 hepatocellular carcinoma HCC 65 refractory systemic anaplastic 64 mucinous 64 castration resistant 64 colorectal carcinoma 64 pan HDAC inhibitor 64 cell lymphoma DLBCL 64 epithelioid 64 small lymphocytic lymphoma 64 paraganglioma 64 Epratuzumab 64 leukemia CML 64 LHRH receptor positive 64 myelofibrosis polycythemia vera 63 gastric carcinoma 63 hepatocellular carcinomas 63 hematologic disorders 63 neuroendocrine carcinoma 63 Squamous 63 complement inhibitor eculizumab 63 histone deacetylase HDAC inhibitor 63 metastatic malignant melanoma 63 acute myeloid 63 imatinib resistant 63 cell carcinomas 63 refractory acute myeloid 63 myelodysplastic syndrome MDS 63 skeletal metastases 63 alkylating agent 63 imatinib Gleevec ® 63 osteosarcoma Ewing sarcoma 63 urothelial carcinoma 63 subependymal giant cell 63 hypercalcemia 63 Hodgkin lymphoma HL 63 Cutaneous T 63 erlotinib Tarceva ® 63 Vidaza azacitidine 63 pemphigus vulgaris 63 erythematosus 63 gastric adenocarcinoma 63 relapsed refractory multiple myeloma 63 Gleevec resistant 63 gefitinib Iressa 63 Sezary syndrome 63 carcinoid tumors 63 carcinoid 63 polycythemia vera PV 63 monoclonal antibody conjugated 63 breast carcinomas 63 prostate carcinomas 63 thyrotoxicosis 63 idiopathic thrombocytopenic purpura ITP 63 hypereosinophilic syndrome 63 tumor xenograft models 63 Leukemias 62 thymoma 62 chronic myeloid 62 Rituxan rituximab 62 myeloproliferative disorders 62 pediatric acute lymphoblastic 62 ovarian carcinoma 62 cell carcinoma 62 metastatic gastric 62 imatinib mesylate 62 lymphadenopathy 62 gastrointestinal stromal tumors GIST 62 gastric cancers 62 cetuximab Erbitux ® 62 bevacizumab Avastin R 62 essential thrombocythemia ET 62 parathyroid carcinoma 62 hematological diseases 62 thalidomide Thalomid 62 AVASTIN 62 fungoides 62 systemic lupus erythematosus 62 Advanced Renal Cell 62 lymphoid malignancies 62 syngeneic 62 prostate cancer mCRPC 62 imatinib Gleevec 62 Waldenstrom macroglobulinemia 62 lymphocytosis 62 ALCL 62 myelodysplastic myeloproliferative diseases 62 metastatic colorectal 62 malignant ascites 62 receptor tyrosine kinase inhibitor 62 cell lymphoma PTCL 62 metastatic renal cell carcinoma 62 sarcomatoid 62 liver metastasis 62 colorectal gastric 62 adriamycin 62 cetuximab Erbitux R 62 Diffuse Large B 62 prostate carcinoma 62 lupus erythematosus 62 myeloproliferative diseases 62 Glioblastoma Multiforme 62 refractory chronic myeloid 62 mycosis fungoides 62 bullous 62 Gleevec imatinib mesylate 62 Carcinoma 62 familial amyloidotic polyneuropathy FAP 62 Carcinoid tumors 62 Myelodysplastic Syndrome MDS 62 castrate resistant prostate cancer 62 superficial bladder cancer 62 Toxicities 62 immunomodulatory therapy 62 refractory multiple myeloma 62 corticosteroid dexamethasone 62 cutaneous T 62 axitinib 61 squamous cell carcinoma SCC 61 recurrent NSCLC 61 B Cell Lymphoma 61 intraepithelial neoplasia 61 superficial basal cell carcinoma 61 paragangliomas 61 leukoencephalopathy 61 fallopian tube cancers 61 relapsed refractory 61 systemic juvenile idiopathic 61 neuroendocrine cancers 61 ADPKD 61 Chronic Myelogenous Leukemia CML 61 pancytopenia 61 Zolinza 61 relapsing remitting MS RRMS 61 cell lymphoma 61 cholangiocarcinoma 61 intestinal metaplasia 61 pancreatic adenocarcinoma 61 CLL SLL 61 HBeAg negative 61 sunitinib Sutent 61 interstitial pneumonitis 61 invasive candidiasis 61 polyposis 61 esophageal candidiasis 61 situ CIS 61 papillary carcinoma 61 lymphocytic leukemia 61 chronic lymphocytic leukemia CLL 61 GISTs 61 Dasatinib 61 cell malignancies 61 treat benign prostatic 61 advanced metastatic renal 61 T Cell Lymphoma 61 Hashimoto thyroiditis 61 adenocarcinomas 61 Paraplatin ® 61 Ribavirin causes 61 Complicated Skin 61 colon carcinoma 61 stage IIIB 61 colorectal pancreatic 61 pancreatic NET 61 T#I mutant 61 pancreatic neuroendocrine tumors 61 Pemetrexed 61 trabectedin 61 malignant lymphoma 61 NAGS deficiency 61 malignant lymphomas 61 hamartomas 61 R Saizen R 61 Lymphomas 61 Nilotinib 61 5alpha reductase 61 recurrent glioblastoma 61 luteinizing hormone releasing 61 liposomal amphotericin B 61 lung carcinomas 61 gemcitabine Gemzar 61 essential thrombocythemia 61 bleomycin 61 cell carcinoma RCC 61 recurrent glioblastoma multiforme 61 haematologic 61 Multiple Myeloma MM 61 transthyretin amyloidosis 61 interleukin IL -# 61 neoplasm 61 MTHFR 61 histological subtype 61 refractory cutaneous T 61 pleomorphic 61 renal tumors 61 Lenalidomide 61 etanercept Enbrel 61 dasatinib Sprycel 61 leiomyomas 61 Cell Lymphoma 61 dasatinib Sprycel ® 61 Philadelphia Chromosome Positive 61 mTOR inhibitor 61 malignant fibrous histiocytoma 60 Personalized Immunotherapy 60 ibritumomab tiuxetan 60 denileukin diftitox 60 malignant pleural mesothelioma 60 sorafenib Nexavar 60 seminoma 60 Atypical Hemolytic Uremic Syndrome 60 hA# 60 severe hypersensitivity reactions 60 cholelithiasis 60 gastrointestinal stromal tumors GISTs 60 gastrointestinal stromal tumors 60 Orally administered 60 neurological manifestations 60 allograft rejection 60 colorectal adenoma 60 purpura ITP 60 erlotinib Tarceva 60 nonmetastatic 60 pulmonary metastases 60 T2DM 60 lymphocytic 60 neoplasia 60 colorectal liver metastases 60 B CLL 60 Hurthle cell 60 FOLOTYN ® 60 non resectable 60 relapsed ovarian cancer 60 Natalizumab 60 cell chronic lymphocytic 60 homozygous familial hypercholesterolemia 60 CYT# potent vascular disrupting 60 Zarnestra 60 hepatorenal syndrome 60 acute humoral rejection 60 endometrial hyperplasia 60 K ras 60 chronic eosinophilic leukemia 60 mycophenolate mofetil 60 cytopenias 60 K ras mutations 60 cutaneous melanoma 60 Wegener granulomatosis 60 castration resistant prostate cancer 60 TNF Tumor Necrosis Factor 60 Neoadjuvant 60 severe malignant osteopetrosis 60 lymphoproliferative disorders 60 neoplasias 60 pT2 60 urothelial bladder cancer 60 chronic thromboembolic pulmonary 60 Vidaza R 60 non metastatic osteosarcoma 60 Kit CD# positive 60 histologic subtype 60 Neuvenge 60 Papillary 60 anterior uveitis 60 Ceflatonin 60 operable breast cancer 60 endometrial carcinoma 60 HDACi 60 minimally symptomatic metastatic castrate 60 oral prodrug 60 androgen independent 60 TO AVOID PREGNANCY WHILE 60 gemcitabine carboplatin 60 medullary thyroid cancer 60 epithelial ovarian 60 HBeAg positive 60 transplantation HSCT 60 cancer mCRC 60 cediranib 60 idiopathic myelofibrosis 60 HNSCC 60 primary peritoneal 60 diagnostic biomarker 60 efalizumab 60 leukaemias 60 NMIBC 60 colorectal adenocarcinoma 60 bendamustine 60 myelodysplastic syndromes 60 herpes zoster shingles 60 grade gliomas 60 Carcinomas 60 chronic myelogenous leukemia CML 60 Zavesca R 59 secondary hyperparathyroidism 59 Gleevec imatinib 59 metastatic neuroendocrine tumors 59 metastatic pancreatic 59 Clolar ® 59 Myelodysplastic Syndrome 59 tumor lysis syndrome 59 mRCC 59 gemcitabine Gemzar ® 59 intravesical therapy 59 selective modulator 59 node metastasis 59 T1a 59 efaproxiral 59 MAGE A3 ASCI 59 Endometrial 59 Systemic lupus erythematosus 59 papillary thyroid carcinoma 59 non squamous 59 macroalbuminuria 59 breast carcinoma 59 Cell Lymphoma CTCL 59 EGFR tyrosine kinase inhibitors 59 acute leukemias 59 Relapsed Refractory 59 Neulasta ® 59 myelofibrosis 59 metastatic castration resistant 59 T#I [002] 59 cutaneous T cell 59 deletion 5q 59 mesotheliomas 59 SSc 59 antiproliferative effects 59 NSCLC tumors 59 Hepatocellular Carcinoma HCC 59 systemic lupus erythematosus SLE 59 Refractory Hodgkin Lymphoma 59 demonstrated antitumor activity 59 nonsmall cell lung cancer 59 PsA 59 neoplastic lesions 59 squamous 59 PNP inhibitor 59 virus HCV protease inhibitor 59 resistant hormone refractory 59 keloid scarring 59 proteasome inhibitor 59 refractory CTCL 59 Chronic lymphocytic leukemia 59 Chronic lymphocytic leukemia CLL 59 pancreatic carcinoma 59 indolent NHL 59 liposomal doxorubicin 59 Camptosar ® 59 allogeneic bone marrow 59 minimally symptomatic 59 isoenzyme 59 anaplastic 59 Malignant Melanoma 59 deep venous thromboses 59 metastatic GIST 59 myelofibrosis MF 59 grade glioma 59 PegIntron 59 depsipeptide 59 psoriatic arthritis PsA 59 PAOD 59 Pharmacokinetics PK 59 autoantibody positive 59 V#F mutation 59 unresectable tumors 59 Hematologic 59 non resectable metastatic 59 generation purine nucleoside 59 microsphere therapy 59 orthotopic 59 curative resection 59 cytoreduction 59 HuMax CD4 59 candidemia 59 lymphoma subtypes 59 adrenocortical cancer 59 Actinic Keratosis 59 MGd 59 Non Hodgkin 59 papillary 59 Epidermal Growth Factor Receptor 59 Enzastaurin 59 multiple myeloma MM 59 Aplidin 59 atypical hemolytic uremic syndrome 59 Xanafide 59 metastatic bladder 59 malignant pancreatic 59 ANCA associated 59 Erlotinib 59 arthritis PsA 59 acute GvHD 59 XL# inhibits 59 biliary tract cancer 59 myeloproliferative neoplasms 59 recurrent ovarian cancer 59 Upregulation 59 carcinoembryonic antigen 59 leiomyosarcoma 59 ritonavir boosted 59 visilizumab 59 Vidaza ® 59 refractory metastatic colorectal cancer 59 basal cell nevus syndrome 59 Azacitidine 59 Sutent sunitinib 59 cisplatin resistant 59 concurrent chemoradiation 59 recombinant tissue plasminogen 59 follicular lymphoma FL 59 TTR amyloidosis 59 evaluating tivozanib 59 docetaxel Taxotere ® 59 transplantation HCT 59 Taxol paclitaxel 59 Anaplastic 59 mitochondrial toxicity 59 relapsed MM 59 hPAM4 59 Aflibercept 59 paclitaxel Taxol 59 trastuzumab Herceptin ® 59 lymphoproliferative disorder 59 progesterone receptor negative 59 ovarian lung 59 MGUS 59 caspofungin 59 selective kinase inhibitor 59 prostate cancer PCa 59 sunitinib Sutent ® 59 Bronchiectasis 59 SCCHN 59 mTOR inhibitors 59 peritoneal carcinomatosis 59 dexpramipexole 59 myotonic muscular dystrophy 59 neuroendocrine tumors 59 prostate cancer CaP 59 Basal cell 59 nonalcoholic steatohepatitis NASH 59 investigational monoclonal antibody 59 Glioblastoma Multiforme GBM 59 aHUS 59 Vaprisol 59 urothelial cancer 59 systemic fungal infections 59 Apoptone 59 pouchitis 59 rheumatoid arthritis RA psoriatic 58 hyperplastic 58 malignant neoplasms 58 hematopoietic cell 58 polycythemia vera essential thrombocythemia 58 diarrhea predominant irritable 58 bexarotene 58 interferon IFN 58 Letairis ambrisentan 58 INCB# [003] 58 Metastatic breast cancer 58 prostate cancer CRPC 58 hepatocellular cancer 58 tiuxetan 58 lupus nephritis 58 Clusterin 58 Cloretazine 58 intraductal 58 variceal hemorrhage 58 inflammatory myofibroblastic tumor 58 myeloproliferative 58 Metastatic 58 carcinoma HCC 58 zanolimumab 58 kinase inhibition 58 eosinophilic 58 Chronic Lymphocytic Leukemia CLL 58 HoFH 58 IIIb 58 refractory indolent non 58 castrate resistant 58 pleural effusions 58 aripiprazole Abilify 58 Friedreich Ataxia FRDA 58 hepatocellular carcinoma 58 Uricase PEG 58 endometrioid 58 prostate cancer AIPC 58 targeted radiotherapeutic 58 relapsed multiple myeloma 58 unresectable 58 colorectal neoplasms 58 Antitumor Activity 58 panitumumab Vectibix 58 AA amyloidosis 58 leiomyoma 58 tyrosine kinase inhibitors TKIs 58 alefacept 58 Mantle Cell Lymphoma 58 PEG IFN 58 papillomas 58 TELINTRA 58 systemic lupus erythematosus psoriasis 58 mu opioid receptor antagonist 58 ara C 58 huC# DM4 58 ^ sup #m 58 Glucocorticoids 58 lymphoma CTCL 58 Idiopathic Pulmonary Fibrosis 58 allogeneic HSCT 58 erythematosus SLE 58 sodium thiosulfate STS 58 tumor necrosis 58 neurofibromas 58 Candida infection 58 fosbretabulin 58 Certolizumab pegol 58 thromboembolic events 58 lobular carcinomas 58 pegylated liposomal doxorubicin 58 SPRYCEL ® 58 renal carcinoma 58 CTAP# Capsules 58 severe neutropenia 58 cervical carcinoma 58 JAK2 V#F 58 Irinotecan 58 cytogenetic responses 58 advanced hepatocellular carcinoma 58 EGFR mutant 58 VEGF inhibitors 58 nodal metastasis 58 hyperplasia 58 benign neoplasms 58 irinotecan containing 58 KRAS wild 58 sodium glucose cotransporter 58 Deforolimus 58 paroxysmal nocturnal hemoglobinuria PNH 58 Legg Calvé Perthes disease 58 gastric carcinomas 58 adenocarcinoma 58 lenalidomide dexamethasone 58 kidney urologic 58 Epstein Barr virus EBV 58 anti angiogenic agents 58 PEGylated interferon beta 1a 58 lenalidomide Revlimid 58 prostate cancer HRPC 58 Nexavar tablets 58 refractory gout 58 Annamycin 58 metaplasia 58 non Hodgkin lymphomas 58 intraepithelial 58 Sudhir Agrawal D.Phil 58 MPGN 58 ON #.Na 58 resectable 58 Interferon Alfa 58 Proxinium TM 58 liposomal formulation 58 gastric cardia 58 bladder cancers 58 premalignant 58 Follicular Lymphoma 58 bronchogenic carcinoma 58 adenomatous 58 alvespimycin 58 Amrubicin 58 imatinib resistance 58 epithelial ovarian cancer 58 Traficet EN 58 mouse xenograft models 58 lung adenocarcinomas 58 Fludarabine 58 node metastases 58 ankylosing spondylitis AS 58 posaconazole 58 recurrent colorectal cancer 58 bevacizumab Avastin ® 58 IMA# 58 hyperphenylalaninemia HPA due 58 ERBB2 58 recurrent GBM 58 EGFR HER2 58 Hypotension 58 colon tumors 58 Elagolix 58 thromboembolic disease 58 astrocytomas 58 MKC# MT 58 TTR gene 58 assessing T DM1 58 haematological malignancies 58 nasopharyngeal carcinoma 58 histone deacetylase inhibitor 58 Histologically 58 surgically resected 58 Dapagliflozin 58 p# MAP kinase inhibitor 58 TKI therapy 58 hydroxymethyl coenzyme 58 voriconazole 58 follicular thyroid cancer 58 gouty arthritis 58 micafungin 58 Antiviral Therapy 58 carcinoid tumor 58 ORENCIA ® 58 meropenem 58 INVANZ 58 orally administered inhibitor 58 Hepatocellular Carcinoma 58 ovarian breast 58 Alessandro Riva 58 PEGylated anti 58 targeted antifolate 58 peritumoral brain edema 58 lobular carcinoma 58 refractory Hodgkin lymphoma 58 pancreatic neuroendocrine 58 hemorrhagic cystitis 58 ulcerative colitis UC 58 prostate adenocarcinoma 58 Aurora kinase 58 HLA DR4 58 recurrent metastatic 58 PROCRIT ® 58 ALK inhibitor 58 LNCaP cells 57 humanised monoclonal antibody 57 autoimmune hemolytic anemia 57 IV NSCLC 57 aneurysms AAA 57 disease GERD 57 lymphomas leukemias 57 posterior uveitis 57 SOD2 gene 57 PEGylated Fab fragment 57 Safinamide 57 lymphomas 57 JMML 57 chronic myeloid leukemia CML 57 Bazedoxifene 57 PEGINTRON TM 57 dose cohort 57 idarubicin 57 anticancer compound 57 metastatic carcinoma 57 chemotherapy cisplatin 57 Estrogen Receptor 57 pegfilgrastim 57 refractory gastrointestinal stromal 57 soft tissue sarcomas 57 gastrointestinal perforation 57 FOLFOX6 57 azole 57 polypoid 57 renal cell carcinoma 57 peripheral blood mononuclear 57 metastatic adenocarcinoma 57 neovascular diseases 57 Doxil ® 57 Combination REOLYSIN R 57 monocytic 57 NPM1 57 SAR# [004] 57 brivanib 57 Allogeneic 57 hematologic malignancies 57 acute myelogenous leukemia AML 57 carcinomas 57 pleural mesothelioma 57 temsirolimus Torisel ® 57 Flu Cy 57 EGFR TKI 57 Fludara ® 57 ZOLINZA 57 FISH fluorescence 57 ductal adenocarcinoma 57 endometrial cancers 57 Bortezomib 57 bortezomib Velcade ® 57 Severe Sepsis 57 plus DOXIL 57 phase IIb clinical 57 PKC# 57 urothelial 57 IV melanoma 57 XmAb# 57 Adenocarcinoma 57 ALK inhibitors 57 neoplastic 57 doxorubicin HCl liposome injection 57 ceftazidime 57 LHRH agonists 57 Radiation Therapy SIRT 57 trastuzumab Herceptin 57 rs# [004] 57 nucleoside analog 57 lymph node metastasis 57 Azedra 57 Acute myeloid leukemia 57 lung pancreatic 57 indolent follicular non 57 atypical Hemolytic Uremic Syndrome 57 Diabetic Neuropathy 57 androgen receptor AR 57 tigecycline 57 heterozygous FH 57 lung metastasis 57 docetaxel Taxotere R 57 sulfasalazine 57 basiliximab 57 ductal breast cancer 57 intrahepatic 57 geographic atrophy 57 Sorafenib 57 hyperplasia BPH 57 Nexavar sorafenib 57 immune globulin intravenous 57 malignant neoplasm 57 tanespimycin 57 multikinase inhibitor 57 MELAS 57 non alcoholic steatohepatitis 57 interferon alfa 2b 57 mediated inhibition 57 BRAF inhibitor 57 Dacogen decitabine 57 refractory ovarian cancer 57 AZT zidovudine Retrovir 57 Myeloid 57 phase IIb trial 57 situ LCIS 57 Acute myeloid leukemia AML 57 BARACLUDE ® 57 EGFR mutation 57 pamidronate 57 beta 1a 57 CTAP# 57 Patients Treated With 57 IGF IR 57 vemurafenib 57 oral ridaforolimus 57 GRASPA ® 57 relapsed leukemia 57 multicentric 57 TNF α 57 thyroid carcinoma 57 Genentech Rituxan 57 acid phosphatase PAP 57 lichen planus 57 myelodysplastic syndromes MDS 57 superficial femoral 57 IL 1ß 57 pediatric malignancies 57 Apolipoprotein B 57 PNET 57 CD# monoclonal antibody 57 Telintra 57 Tarceva TM 57 pharmacokinetic interactions 57 differentiated thyroid 57 Randomized Phase 57 Navelbine ® 57 Tezampanel 57 AEGR 57 FLT3 57 lymphoid tumors 57 duodenal ulcer 57 VNP#M 57 haematologic malignancies 57 trans retinoic acid 57 calcineurin inhibitor 57 metastatic hormone refractory 57 Chronic Hepatitis C 57 retinoic acid receptor 57 noninfectious uveitis 57 diabetic nephropathy 57 invasive aspergillosis 57 Bezielle 57 ductal carcinomas 57 intravenous immunoglobulin 57 Barrett esophagus BE 57 primary hyperparathyroidism 57 sphingosine 1 57 Tarceva erlotinib 57 investigational humanized monoclonal antibody 57 refractory Hodgkin 57 capecitabine Xeloda 57 PTLD 57 GW# [003] 57 Renal Cell Carcinoma RCC 57 lactate dehydrogenase 57 echinocandin 57 KRAS mutant 57 elacytarabine 57 Occlusive Disease 57 resistant ovarian cancer 57 cTnI 57 parathyroid 57 Denufosol 57 carcinoids 57 tyrosine kinase receptor 57 BCG refractory carcinoma 57 immune thrombocytopenic purpura 57 pediatric Crohn disease 57 erythema nodosum 57 Systemic lupus erythematosus SLE 57 prokinetic agent 57 fluoropyrimidine 57 temsirolimus Torisel 57 cervical lymph nodes 57 Tigecycline 57 LymphoStat B belimumab 57 tuberous sclerosis TS 57 HMG CoA reductase inhibitors 57 Chronic Lymphocytic Leukemia 57 Pralatrexate 57 metaglidasen 57 Gorlin syndrome 57 atypical ductal hyperplasia 57 Solazed TM 57 rituximab Rituxan 57 benign prostatic hypertrophy BPH 57 vorinostat 57 pancreatic prostate 57 WT1 57 aplastic anemia AA 57 targeting CD# 57 Vorinostat 57 chronic idiopathic thrombocytopenic purpura 57 HER2/neu 57 Asymptomatic 57 MAPK pathway 57 cetuximab Erbitux 57 non squamous NSCLC 57 ixabepilone 57 intestinal polyps 57 mapatumumab 57 doxorubicin Adriamycin 57 relapsing multiple sclerosis 57 ribavirin Copegus ® 57 adjuvant radiotherapy 57 purpura 57 grade cervical dysplasia 57 polycythemia vera 57 sJIA 57 prostate TURP 57 Chemokine Receptor 57 AML MDS 57 myelomas 57 HER2 overexpression 57 irinotecan hydrochloride 57 galiximab 57 pancreatic islet cell 57 severe oral mucositis 57 Cholangiocarcinoma 57 pertuzumab 57 AA Amyloidosis 57 Metastatic Colorectal Cancer 57 Phase #b/#a clinical 57 CLORETAZINE TM VNP#M 57 PCNSL 57 Non Alcoholic Steatohepatitis 57 DAVANAT 57 neoadjuvant 57 mTOR mammalian target 57 previously untreated follicular 57 Pseudomonas aeruginosa infections 57 unknown etiology 57 osteochondroma 57 bladder ovarian 57 forodesine 57 ductal cancer 57 Achieves Primary Endpoint 57 Relapsed 57 atypical hyperplasia 57 dual endothelin receptor antagonist 57 soluble tumor necrosis 57 primary hypercholesterolemia 57 lymphoid cells 57 Daclizumab 57 precancerous condition 57 Bosutinib 57 symptomatic paroxysmal AF 57 molecule epidermal 57 selectively binds 57 HuMax EGFr 57 Leucovorin 57 sclerosing 57 SIR Spheres 57 Bleomycin 57 Quinamed 57 Tumor Necrosis Factor 57 oropharyngeal candidiasis OPC 57 grade prostatic intraepithelial 57 Motesanib 57 refractory lymphoma 57 neoplasia PIN 57 pT3 56 cytokeratin 56 hypointense 56 tumoral 56 peritoneal cancer 56 opioid induced constipation OIC 56 gene polymorphism 56 rFVIIa 56 bone metastasis 56 mastocytosis 56 MabCampath 56 huN# DM1 56 solar keratosis 56 Platinol ® 56 receptor blockers 56 Pivotal Phase III 56 Fingolimod 56 ABCB1 56 RezularTM 56 relapsed acute myelogenous 56 BRAF V#E 56 cystic lesions 56 HeFH 56 BRAF mutations 56 Mitomycin C 56 pancreatic ductal adenocarcinoma 56 carcinomatosis 56 serous ovarian cancer 56 BRCA1 BRCA2 56 novel histone deacetylase 56 irreversible inhibitor 56 PRTX 56 xenograft tumors 56 refractory diffuse 56 radiation sensitizer 56 metastatic colorectal carcinoma 56 non splenectomized 56 chemoresistant 56 squamous cell lung cancer 56 malignant pheochromocytoma 56 Previously Treated 56 thrombocytosis 56 chemoresistance 56 Benlysta belimumab 56 Follicular lymphoma 56 Amgen Neulasta R 56 neoplasia CIN 56 Kinase Inhibitor 56 Hormone Refractory Prostate Cancer 56 transitional cell carcinoma 56 adenomatous polyps 56 Cell Lung Cancer 56 Crohn disease CD 56 platinum refractory 56 vandetanib 56 BAY #-# 56 candesartan cilexetil 56 angiogenesis inhibitor 56 adventitia 56 underwent resection 56 RoACTEMRA 56 chronic HBV 56 Taxotere chemotherapy 56 Vicinium TM 56 JAK inhibitor 56 chemosensitivity 56 myeloid 56 chronic granulomatous disease 56 Zollinger Ellison Syndrome 56 Riluzole 56 Pegylated 56 Oral Mucositis 56 Randomized Study 56 terlipressin 56 Randomized Double Blind Placebo